Press Room

INTERPHEX Week Tokyo 2025

Start
Wednesday, July 09, 2025
End
Friday, July 11, 2025
Location: Tokyo, Japan
Booth Number: W1-29

Hovione is exhibiting at INTERPHEX Week Tokyo, a renowned meeting place for the pharmaceutical industry, bringing together worldwide professionals and leading companies for networking and business opportunities. 

Meet the Hovione team at booth # W1-29

  • Gain insights on how Hovione is addressing solubility and bioavailability challenges and how, with our unrivalled expertise in formulation development, scale-up and GMP manufacturing, we can support you in developing novel drugs that make a difference for patients.
  • Understand how we ensure your inhalation and nasal therapies are engineered for success, from start to finish. With active business in Japan since the 1960s, Hovione is the right partner when looking for a one-site solution that includes a full range of innovative devices.
  • Learn how our latest technologies and innovations in drug product development can support your projects providing optimal solutions with the right scale and flexibility. 

Yuken Kyoyama and Yasushi Usuda are looking forward to meeting you.

 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026